25 XP 0   0   10  
0coffee
Main menu
3rd party ad coffee SUPPORTERis ad-free.

Benitec Biopharma Ltd ADR
Buy, Hold or Sell?

Let's analyze Benitec together

I guess you are interested in Benitec Biopharma Ltd ADR. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Benitec Biopharma Ltd ADR. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

Get notifications about Benitec Biopharma Ltd ADR

I send you an email if I find something interesting about Benitec Biopharma Ltd ADR.

1. Quick Overview

1.1. Quick analysis of Benitec (30 sec.)










1.2. What can you expect buying and holding a share of Benitec? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
$3.24
Expected worth in 1 year
$5.35
How sure are you?
35.0%

+ What do you gain per year?

Total Gains per Share
$2.11
Return On Investment
18.0%

For what price can you sell your share?

Current Price per Share
$11.77
Expected price per share
$10.93 - $
How sure are you?
50%
3rd party ad coffee SUPPORTERis ad-free.

2. Detailed Analysis

2.1. Valuation of Benitec (5 min.)




Live pricePrice per Share (EOD)
$11.77
Intrinsic Value Per Share
$-7.54 - $-8.69
Total Value Per Share
$-4.30 - $-5.45

2.2. Growth of Benitec (5 min.)




Is Benitec growing?

Current yearPrevious yearGrowGrow %
How rich?$64.1m$9m$25.5m73.8%

How much money is Benitec making?

Current yearPrevious yearGrowGrow %
Making money-$5.2m-$5m-$142.2k-2.7%
Net Profit Margin-17,829.2%-28,018.4%--

How much money comes from the company's main activities?

2.3. Financial Health of Benitec (5 min.)




2.4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#420 / 944

Most Revenue
#776 / 944

Most Profit
#440 / 944

Most Efficient
#891 / 944
3rd party ad coffee SUPPORTERis ad-free.

3. Summary and Key Metrics

3.1. What can you expect buying and holding a share of Benitec?

Welcome investor! Benitec's management wants to use your money to grow the business. In return you get a share of Benitec.

First you should know what it really means to hold a share of Benitec. And how you can make/lose money.

Speculation

The Price per Share of Benitec is $11.77. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Benitec.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Benitec, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $3.24. Based on the TTM, the Book Value Change Per Share is $0.53 per quarter. Based on the YOY, the Book Value Change Per Share is $0.10 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Benitec.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps-0.26-2.2%-0.26-2.2%-0.26-2.2%-0.22-1.8%-0.20-1.7%
Usd Book Value Change Per Share0.857.3%0.534.5%0.100.8%0.161.4%0.050.4%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share0.857.3%0.534.5%0.100.8%0.161.4%0.050.4%
Usd Price Per Share9.19-6.17-0.91-3.70-3.22-
Price to Earnings Ratio-9.00--6.19--0.79--5.02--9.60-
Price-to-Total Gains Ratio10.75--5.23-0.02--7.90--6.12-
Price to Book Ratio2.84-4.74-6.83-6.55-8.16-
Price-to-Total Gains Ratio10.75--5.23-0.02--7.90--6.12-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share11.77
Number of shares84
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share0.530.16
Usd Total Gains Per Share0.530.16
Gains per Quarter (84 shares)44.3813.54
Gains per Year (84 shares)177.5054.17
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
1017816805444
20355346010898
305335240163152
407107020217206
508888800271260
60106510580325314
70124312360379368
80142014140433422
90159815920488476
100177517700542530

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.04.00.00.0%0.012.00.00.0%0.020.00.00.0%5.034.01.012.5%5.035.02.011.9%
Book Value Change Per Share2.02.00.050.0%4.08.00.033.3%7.012.01.035.0%14.023.03.035.0%16.023.03.038.1%
Dividend per Share0.00.04.00.0%0.00.012.00.0%0.00.020.00.0%0.00.040.00.0%0.00.042.00.0%
Total Gains per Share2.02.00.050.0%4.08.00.033.3%7.012.01.035.0%14.023.03.035.0%16.023.03.038.1%
3rd party ad coffee SUPPORTERis ad-free.

3.2. Key Performance Indicators

The key performance indicators of Benitec Biopharma Ltd ADR compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share--0.8550.528+62%0.097+780%0.161+430%0.053+1524%
Book Value Per Share--3.2391.746+85%0.457+609%0.807+301%0.772+320%
Current Ratio--15.0098.326+80%3.379+344%8.182+83%11.420+31%
Debt To Asset Ratio--0.0670.168-60%0.450-85%0.224-70%0.149-55%
Debt To Equity Ratio--0.0720.215-67%5.595-99%1.306-95%0.693-90%
Dividend Per Share----0%-0%-0%-0%
Enterprise Value--245346850.000155734225.000+58%25533145.375+861%87025490.249+182%83053993.936+195%
Eps---0.255-0.263+3%-0.261+2%-0.217-15%-0.197-23%
Ev To Ebitda Ratio---10.761-7.221-33%-1.135-89%-5.947-45%infnan%
Ev To Sales Ratio--infinfnan%infnan%infnan%infnan%
Free Cash Flow Per Share---0.231-0.248+7%-0.234+1%-0.198-14%-0.154-33%
Free Cash Flow To Equity Per Share--0.8610.533+62%0.117+637%0.255+238%0.127+581%
Gross Profit Margin--1.0001.009-1%1.0000%1.0020%0.976+2%
Intrinsic Value_10Y_max---8.691--------
Intrinsic Value_10Y_min---7.544--------
Intrinsic Value_1Y_max---0.903--------
Intrinsic Value_1Y_min---0.887--------
Intrinsic Value_3Y_max---2.688--------
Intrinsic Value_3Y_min---2.566--------
Intrinsic Value_5Y_max---4.444--------
Intrinsic Value_5Y_min---4.127--------
Market Cap233222550.000+22%182099850.000122159475.000+49%18032145.375+910%73312329.600+148%71630018.250+154%
Net Profit Margin----178.2920%-280.1840%-701.5100%-361.4420%
Operating Margin----178.1250%-285.6330%-672.4410%-345.5160%
Operating Ratio---172.667-100%287.406-100%689.397-100%357.939-100%
Pb Ratio3.634+22%2.8374.738-40%6.834-58%6.554-57%8.165-65%
Pe Ratio-11.525-28%-8.999-6.192-31%-0.787-91%-5.015-44%-9.597+7%
Price Per Share11.770+22%9.1906.165+49%0.910+910%3.700+148%3.224+185%
Price To Free Cash Flow Ratio-12.714-28%-9.927-6.869-31%-0.990-90%-5.564-44%-7.791-22%
Price To Total Gains Ratio13.774+22%10.755-5.234+149%0.022+47767%-7.903+173%-6.121+157%
Quick Ratio--14.9018.245+81%3.177+369%7.291+104%9.759+53%
Return On Assets---0.074-0.192+161%-0.561+663%-0.333+353%-0.307+317%
Return On Equity---0.079-0.248+214%-6.217+7787%-1.549+1866%-0.926+1075%
Total Gains Per Share--0.8550.528+62%0.097+780%0.161+430%0.053+1524%
Usd Book Value--64180000.00034599500.000+85%9054250.000+609%15996252.015+301%15745875.355+308%
Usd Book Value Change Per Share--0.8550.528+62%0.097+780%0.161+430%0.053+1524%
Usd Book Value Per Share--3.2391.746+85%0.457+609%0.807+301%0.772+320%
Usd Dividend Per Share----0%-0%-0%-0%
Usd Enterprise Value--245346850.000155734225.000+58%25533145.375+861%87025490.249+182%83053993.936+195%
Usd Eps---0.255-0.263+3%-0.261+2%-0.217-15%-0.197-23%
Usd Free Cash Flow---4586000.000-4915281.250+7%-4636250.000+1%-3932401.713-14%-3023136.657-34%
Usd Free Cash Flow Per Share---0.231-0.248+7%-0.234+1%-0.198-14%-0.154-33%
Usd Free Cash Flow To Equity Per Share--0.8610.533+62%0.117+637%0.255+238%0.127+581%
Usd Market Cap233222550.000+22%182099850.000122159475.000+49%18032145.375+910%73312329.600+148%71630018.250+154%
Usd Price Per Share11.770+22%9.1906.165+49%0.910+910%3.700+148%3.224+185%
Usd Profit---5059000.000-5214000.000+3%-5071750.000+0%-4305500.000-15%-2901806.689-43%
Usd Revenue---1500.000-100%18750.000-100%38852.100-100%615234.557-100%
Usd Total Gains Per Share--0.8550.528+62%0.097+780%0.161+430%0.053+1524%
 EOD+6 -2MRQTTM+31 -4YOY+31 -35Y+25 -1010Y+25 -9

3.3 Fundamental Score

Let's check the fundamental score of Benitec Biopharma Ltd ADR based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-11.525
Price to Book Ratio (EOD)Between0-13.634
Net Profit Margin (MRQ)Greater than00.000
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than114.901
Current Ratio (MRQ)Greater than115.009
Debt to Asset Ratio (MRQ)Less than10.067
Debt to Equity Ratio (MRQ)Less than10.072
Return on Equity (MRQ)Greater than0.15-0.079
Return on Assets (MRQ)Greater than0.05-0.074
Total4/10 (40.0%)

3.4 Technical Score

Let's check the technical score of Benitec Biopharma Ltd ADR based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5056.911
Ma 20Greater thanMa 5010.653
Ma 50Greater thanMa 10010.548
Ma 100Greater thanMa 2009.731
OpenGreater thanClose12.450
Total5/5 (100.0%)

4. In-depth Analysis

4.1 About Benitec Biopharma Ltd ADR

Benitec Biopharma Inc., a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference-based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy. Benitec Biopharma Inc. was incorporated in 1995 and is headquartered in Hayward, California.

Fundamental data was last updated by Penke on 2024-12-05 14:27:04.

4.2 In-depth Summary

4.2.1. Financial Health Summary

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

4.2.2. Valuation Summary

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is fair priced.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.
3rd party ad coffee SUPPORTERis ad-free.

4.3 Financial Health

4.3.1. Profitability

4.3.1 Profitability
4.3.1.1. Net Profit Margin

Measures how much net profit Benitec earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Benitec to the Biotechnology industry mean.
  • A Net Profit Margin of 0.0% means that $0.00 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Benitec Biopharma Ltd ADR:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-17,829.2%+17,829.2%
TTM-17,829.2%YOY-28,018.4%+10,189.2%
TTM-17,829.2%5Y-70,151.0%+52,321.9%
5Y-70,151.0%10Y-36,144.2%-34,006.8%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--108.6%+108.6%
TTM-17,829.2%-221.4%-17,607.8%
YOY-28,018.4%-207.4%-27,811.0%
5Y-70,151.0%-346.2%-69,804.8%
10Y-36,144.2%-470.4%-35,673.8%
4.3.1.2. Return on Assets

Shows how efficient Benitec is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Benitec to the Biotechnology industry mean.
  • -7.4% Return on Assets means that Benitec generated $-0.07 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Benitec Biopharma Ltd ADR:

  • The MRQ is -7.4%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -19.2%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-7.4%TTM-19.2%+11.8%
TTM-19.2%YOY-56.1%+36.9%
TTM-19.2%5Y-33.3%+14.1%
5Y-33.3%10Y-30.7%-2.6%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-7.4%-11.6%+4.2%
TTM-19.2%-12.0%-7.2%
YOY-56.1%-11.2%-44.9%
5Y-33.3%-12.6%-20.7%
10Y-30.7%-14.1%-16.6%
4.3.1.3. Return on Equity

Shows how efficient Benitec is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Benitec to the Biotechnology industry mean.
  • -7.9% Return on Equity means Benitec generated $-0.08 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Benitec Biopharma Ltd ADR:

  • The MRQ is -7.9%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -24.8%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-7.9%TTM-24.8%+16.9%
TTM-24.8%YOY-621.7%+596.9%
TTM-24.8%5Y-154.9%+130.2%
5Y-154.9%10Y-92.6%-62.3%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-7.9%-14.5%+6.6%
TTM-24.8%-16.0%-8.8%
YOY-621.7%-14.6%-607.1%
5Y-154.9%-18.5%-136.4%
10Y-92.6%-19.2%-73.4%
3rd party ad coffee SUPPORTERis ad-free.

4.3.2. Operating Efficiency of Benitec Biopharma Ltd ADR.

4.3.2. Operating Efficiency
4.3.2.1. Operating Margin

Measures how efficient Benitec is operating .

  • Measures how much profit Benitec makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Benitec to the Biotechnology industry mean.
  • An Operating Margin of 0.0% means the company generated $0.00  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Benitec Biopharma Ltd ADR:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-17,812.5%+17,812.5%
TTM-17,812.5%YOY-28,563.3%+10,750.8%
TTM-17,812.5%5Y-67,244.1%+49,431.6%
5Y-67,244.1%10Y-34,551.6%-32,692.4%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--204.0%+204.0%
TTM-17,812.5%-316.8%-17,495.7%
YOY-28,563.3%-215.6%-28,347.7%
5Y-67,244.1%-376.1%-66,868.0%
10Y-34,551.6%-480.3%-34,071.3%
4.3.2.2. Operating Ratio

Measures how efficient Benitec is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 0.00 means that the operating costs are $0.00 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Benitec Biopharma Ltd ADR:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM172.667-172.667
TTM172.667YOY287.406-114.739
TTM172.6675Y689.397-516.731
5Y689.39710Y357.939+331.458
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-2.284-2.284
TTM172.6673.198+169.469
YOY287.4063.247+284.159
5Y689.3974.651+684.746
10Y357.9396.419+351.520
3rd party ad coffee SUPPORTERis ad-free.

4.4.3. Liquidity of Benitec Biopharma Ltd ADR.

4.4.3. Liquidity
4.4.3.1. Current Ratio

Measures if Benitec is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 15.01 means the company has $15.01 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Benitec Biopharma Ltd ADR:

  • The MRQ is 15.009. The company is very able to pay all its short-term debts. +2
  • The TTM is 8.326. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ15.009TTM8.326+6.683
TTM8.326YOY3.379+4.946
TTM8.3265Y8.182+0.143
5Y8.18210Y11.420-3.238
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ15.0093.586+11.423
TTM8.3263.869+4.457
YOY3.3794.644-1.265
5Y8.1825.971+2.211
10Y11.4206.240+5.180
4.4.3.2. Quick Ratio

Measures if Benitec is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Benitec to the Biotechnology industry mean.
  • A Quick Ratio of 14.90 means the company can pay off $14.90 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Benitec Biopharma Ltd ADR:

  • The MRQ is 14.901. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 8.245. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ14.901TTM8.245+6.656
TTM8.245YOY3.177+5.068
TTM8.2455Y7.291+0.954
5Y7.29110Y9.759-2.468
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ14.9013.093+11.808
TTM8.2453.392+4.853
YOY3.1774.304-1.127
5Y7.2915.953+1.338
10Y9.7596.435+3.324
3rd party ad coffee SUPPORTERis ad-free.

4.5.4. Solvency of Benitec Biopharma Ltd ADR.

4.5.4. Solvency
4.5.4.1. Debt to Asset Ratio

Measures how much % of Benitec assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Benitec to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.07 means that Benitec assets are financed with 6.7% credit (debt) and the remaining percentage (100% - 6.7%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Benitec Biopharma Ltd ADR:

  • The MRQ is 0.067. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.168. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.067TTM0.168-0.101
TTM0.168YOY0.450-0.283
TTM0.1685Y0.224-0.057
5Y0.22410Y0.149+0.075
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.0670.346-0.279
TTM0.1680.347-0.179
YOY0.4500.313+0.137
5Y0.2240.365-0.141
10Y0.1490.383-0.234
4.5.4.2. Debt to Equity Ratio

Measures if Benitec is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Benitec to the Biotechnology industry mean.
  • A Debt to Equity ratio of 7.2% means that company has $0.07 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Benitec Biopharma Ltd ADR:

  • The MRQ is 0.072. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.215. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.072TTM0.215-0.144
TTM0.215YOY5.595-5.380
TTM0.2155Y1.306-1.091
5Y1.30610Y0.693+0.613
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.0720.393-0.321
TTM0.2150.432-0.217
YOY5.5950.388+5.207
5Y1.3060.455+0.851
10Y0.6930.498+0.195
3rd party ad coffee SUPPORTERis ad-free.

4.6. Market Valuation

4.6.1. Earnings Per Share
4.6.2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Benitec generates.

  • Above 15 is considered overpriced but always compare Benitec to the Biotechnology industry mean.
  • A PE ratio of -9.00 means the investor is paying $-9.00 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Benitec Biopharma Ltd ADR:

  • The EOD is -11.525. Based on the earnings, the company is expensive. -2
  • The MRQ is -8.999. Based on the earnings, the company is expensive. -2
  • The TTM is -6.192. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-11.525MRQ-8.999-2.526
MRQ-8.999TTM-6.192-2.807
TTM-6.192YOY-0.787-5.405
TTM-6.1925Y-5.015-1.176
5Y-5.01510Y-9.597+4.582
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-11.525-2.180-9.345
MRQ-8.999-2.507-6.492
TTM-6.192-3.153-3.039
YOY-0.787-3.242+2.455
5Y-5.015-5.992+0.977
10Y-9.597-6.690-2.907
4.6.2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Benitec Biopharma Ltd ADR:

  • The EOD is -12.714. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -9.927. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -6.869. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-12.714MRQ-9.927-2.787
MRQ-9.927TTM-6.869-3.058
TTM-6.869YOY-0.990-5.879
TTM-6.8695Y-5.564-1.306
5Y-5.56410Y-7.791+2.227
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-12.714-2.879-9.835
MRQ-9.927-3.276-6.651
TTM-6.869-3.669-3.200
YOY-0.990-4.485+3.495
5Y-5.564-8.015+2.451
10Y-7.791-9.197+1.406
3rd party ad coffee SUPPORTERis ad-free.
4.6.2. Book Value per Share
4.6.2.1. Price to Book Ratio

Measures if the stock price of Benitec is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 2.84 means the investor is paying $2.84 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Benitec Biopharma Ltd ADR:

  • The EOD is 3.634. Based on the equity, the company is fair priced.
  • The MRQ is 2.837. Based on the equity, the company is underpriced. +1
  • The TTM is 4.738. Based on the equity, the company is fair priced.
Trends
Current periodCompared to+/- 
EOD3.634MRQ2.837+0.797
MRQ2.837TTM4.738-1.901
TTM4.738YOY6.834-2.096
TTM4.7385Y6.554-1.816
5Y6.55410Y8.165-1.611
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD3.6341.964+1.670
MRQ2.8372.056+0.781
TTM4.7382.388+2.350
YOY6.8342.460+4.374
5Y6.5543.697+2.857
10Y8.1654.324+3.841
4.6.2. Total Gains per Share

4.7 Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Benitec Biopharma Ltd ADR.

4.8.1. Institutions holding Benitec Biopharma Ltd ADR

Institutions are holding 46.122% of the shares of Benitec Biopharma Ltd ADR.

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2024-09-30Suvretta Capital Management, LLC38.02932.596188290537137763422.0307
2024-09-30HHG PLC3.77540.0041876523-24293-2.6968
2024-09-30Adage Capital Partners Gp LLC3.62410.013784139500
2024-09-30Nantahala Capital Management, LLC3.60990.3896838095-3300-0.3922
2024-09-30Franklin Resources Inc3.43140.002279664400
2024-09-30Awm Investment Company Inc2.69210.69596250006250000
2024-09-30Schonfeld Strategic Advisors LLC1.17510.0167272817124004.7616
2024-09-30Vanguard Group Inc0.91770213067-2003-0.9313
2024-09-30Simplify Asset Management Inc.0.5020.049911653565319127.5363
2024-09-30Geode Capital Management, LLC0.36180.0001839872001231.281
2024-09-30Armistice Capital, LLC0.25840.008860000600000
2024-09-30Lion Point Capital, LP0.1680.798139000390000
2024-09-30Longwood Capital Partners LLC0.12840.221829800298000
2024-06-30BlackRock Inc0.1206028004280040
2024-09-30Northern Trust Corp0.1067024775-149-0.5978
2024-09-30Ameriprise Financial Inc0.0641014879148790
2024-09-30Citadel Advisors Llc0.0614014244142440
2024-09-30GAMMA Investing LLC0.02820.0066540110220.2648
2024-09-30UBS Group AG0.008301924-108-5.315
2024-09-30Morgan Stanley - Brokerage Accounts0.005701324-9876-88.1786
Total 59.06864.80313713606+8007794+58.4%

4.9.2. Funds holding Benitec Biopharma Ltd ADR

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2024-10-31Franklin Biotechnology Discv A(acc)USD7.07341.126716421991418849635.2581
2024-09-30Franklin Biotechnology Discovery A2.4690.569657322100
2024-10-31Vanguard Institutional Extnd Mkt Idx Tr0.86670.002201221-6572-3.1628
2024-09-30Janus Henderson Hrzn Biotec E2 USD0.5790.307513442234652.6459
2024-10-31Simplify Health Care ETF0.38710.525589869-26666-22.8824
2024-09-30Fidelity Extended Market Index0.21130.001149066-5211-9.6008
2024-08-31RIM Global Bioscience EUR0.12450.220328899288990
2024-09-30BlackRock Extended Equity Market K0.07970.001218502-8-0.0432
2024-09-30Fidelity Total Market Index0.06770.000115721728386.3119
2024-09-30NT Ext Equity Mkt Idx Fd - NL0.06270.0021455000
2024-09-30NT Ext Equity Mkt Idx Fd - DC - NL - T20.05050.00211723360.308
2024-09-30Fidelity Series Total Market Index0.04870.0001113075780104.5775
2024-09-30Northern Trust Extended Eq Market Idx0.04210.0012976500
2024-09-30NT Ext Equity Mkt Idx Fd - L0.04210.0012976500
2024-11-27iShares Micro-Cap ETF0.02420.0055562700
2024-10-31Vanguard U.S. Eq Idx £ Acc0.02270.0003527400
2024-09-30Spartan Extended Market Index Pool E0.01420.000733041908136.6762
2024-09-30Fidelity Nasdaq Composite Index0.01260.0002292500
2024-10-31State St US Extended Mkt Indx NL Cl C0.01230.0016285400
2024-09-30Extended Equity Market Fund M0.01010.00122348-6-0.2549
Total 12.20062.772832562+1427757+50.4%

5.3. Insider Transactions

Insiders are holding 4.388% of the shares of Benitec Biopharma Ltd ADR.

DateOwnerTypeAmountPricePost Transaction AmountLink
2021-12-09Steven Michael OliveiraBUY62051.68
3rd party ad coffee SUPPORTERis ad-free.

5. Financial Statements




5.1. Latest Balance Sheet

Balance Sheet of 2024-09-30. Currency in USD. All numbers in thousands.

Summary
Total Assets68,774
Total Liabilities4,594
Total Stockholder Equity64,180
 As reported
Total Liabilities 4,594
Total Stockholder Equity+ 64,180
Total Assets = 68,774

Assets

Total Assets68,774
Total Current Assets68,335
Long-term Assets439
Total Current Assets
Cash And Cash Equivalents 67,841
Net Receivables 4
Other Current Assets 490
Total Current Assets  (as reported)68,335
Total Current Assets  (calculated)68,335
+/-0
Long-term Assets
Property Plant Equipment 358
Long-term Assets Other 81
Long-term Assets  (as reported)439
Long-term Assets  (calculated)439
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities4,553
Long-term Liabilities41
Total Stockholder Equity64,180
Total Current Liabilities
Short-term Debt 211
Accounts payable 903
Other Current Liabilities 3,439
Total Current Liabilities  (as reported)4,553
Total Current Liabilities  (calculated)4,553
+/-0
Long-term Liabilities
Long-term Liabilities  (as reported)41
Long-term Liabilities  (calculated)0
+/- 41
Total Stockholder Equity
Common Stock1
Retained Earnings -195,318
Accumulated Other Comprehensive Income -993
Other Stockholders Equity 260,490
Total Stockholder Equity (as reported)64,180
Total Stockholder Equity (calculated)64,180
+/-0
Other
Capital Stock1
Cash and Short Term Investments 67,841
Common Stock Shares Outstanding 10,645
Liabilities and Stockholders Equity 68,774
Net Debt -67,630
Net Invested Capital 64,180
Net Working Capital 63,782
Property Plant and Equipment Gross 1,787
Short Long Term Debt Total 211



5.2. Balance Sheets Structured

Currency in USD. All numbers in thousands.

 Trend2024-09-302024-06-302024-03-312023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-06-302013-06-30
> Total Assets 
1,605
24,027
24,819
0
19,574
0
20,596
20,726
14,853
15,785
14,362
19,243
17,418
16,092
13,848
11,447
15,675
21,862
21,316
646
19,207
308
16,306
0
11,587
8,916
15,512
13,428
21,379
17,836
14,014
10,064
5,973
18,115
11,905
8,220
4,464
27,053
21,353
14,999
52,210
68,774
68,77452,21014,99921,35327,0534,4648,22011,90518,1155,97310,06414,01417,83621,37913,42815,5128,91611,587016,30630819,20764621,31621,86215,67511,44713,84816,09217,41819,24314,36215,78514,85320,72620,596019,574024,81924,0271,605
   > Total Current Assets 
0
23,598
24,477
0
19,224
0
20,243
20,269
14,476
15,415
13,945
18,846
17,030
15,710
13,400
11,048
15,349
21,597
21,057
630
18,729
21,920
15,346
12,728
10,809
8,056
14,383
12,407
20,608
16,372
12,672
8,841
4,820
17,081
10,975
7,395
3,729
26,412
20,796
14,366
51,674
68,335
68,33551,67414,36620,79626,4123,7297,39510,97517,0814,8208,84112,67216,37220,60812,40714,3838,05610,80912,72815,34621,92018,72963021,05721,59715,34911,04813,40015,71017,03018,84613,94515,41514,47620,26920,243019,224024,47723,5980
       Cash And Cash Equivalents 
1,455
20,512
21,948
0
16,711
0
16,574
15,223
13,614
10,216
8,840
15,007
13,352
11,532
8,011
8,085
11,816
16,750
16,332
528
15,695
260
13,762
0
9,801
7,450
14,010
11,988
19,769
15,727
12,329
8,630
4,062
16,534
10,537
6,551
2,477
25,864
20,374
14,156
50,866
67,841
67,84150,86614,15620,37425,8642,4776,55110,53716,5344,0628,63012,32915,72719,76911,98814,0107,4509,801013,76226015,69552816,33216,75011,8168,0858,01111,53213,35215,0078,84010,21613,61415,22316,574016,711021,94820,5121,455
       Short-term Investments 
0
0
0
0
0
0
1,456
0
28
0
72
77
77
78
55
33
22
3
3
0
127
0
23
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
63
0
063000000000000000002301270332233557877777202801,456000000
       Net Receivables 
0
116
60
0
189
0
28
25
730
5,025
4,779
3,544
3,386
3,979
4,873
2,429
3,126
4,278
4,171
85
2,532
1,326
928
818
59
18
21
10
25
3
5
5
3
3
68
56
55
53
53
53
229
4
42295353535556683355325102118598189281,3262,532854,1714,2783,1262,4294,8733,9793,3863,5444,7795,025730252801890601160
       Inventory 
0
2,612
0
0
2,128
0
2,176
2,256
111
157
243
0
-65
0
0
0
0
0
0
0
0
0
0
0
948
587
0
0
0
0
0
0
0
0
0
14
13
13
14
0
63
0
06301413131400000000058794800000000000-6502431571112,2562,17602,128002,6120
   > Long-term Assets 
0
429
342
0
350
0
354
457
378
370
417
397
387
382
449
398
326
0
259
0
478
0
960
0
778
860
1,129
1,021
771
1,464
1,342
1,223
1,153
1,034
930
825
735
641
527
633
536
439
4395366335276417358259301,0341,1531,2231,3421,4647711,0211,1298607780960047802590326398449382387397417370378457354035003424290
       Property Plant Equipment 
26
429
342
0
350
0
354
457
378
325
374
352
342
336
321
273
234
198
193
670
469
1,358
951
843
769
851
910
815
577
1,270
1,156
1,042
993
890
789
695
613
531
451
539
449
358
3584495394515316136957898909931,0421,1561,2705778159108517698439511,3584696701931982342733213363423523743253784573540350034242926
       Other Assets 
0
0
0
0
0
0
0
0
0
45
0
45
0
46
0
56
36
67
23
13
13
13
0
9
9
9
219
206
194
194
186
181
160
144
141
0
122
0
30
0
0
0
0003001220141144160181186194194206219999013131323673656046045045000000000
> Total Liabilities 
1,018
1,546
588
0
1,259
0
730
1,706
786
732
1,005
897
891
1,361
1,420
1,316
1,906
1,553
1,514
89
2,637
20
1,083
0
1,349
1,180
887
2,498
1,369
2,361
3,178
2,544
3,091
3,502
2,911
3,507
4,262
4,745
5,883
3,499
4,962
4,594
4,5944,9623,4995,8834,7454,2623,5072,9113,5023,0912,5443,1782,3611,3692,4988871,1801,34901,083202,637891,5141,5531,9061,3161,4201,3618918971,0057327861,70673001,25905881,5461,018
   > Total Current Liabilities 
1,018
1,546
588
0
1,259
0
730
1,693
773
710
985
871
865
1,333
1,390
1,281
1,871
1,547
1,508
89
2,637
1,080
756
981
1,136
1,019
779
2,444
1,369
1,601
2,480
1,909
2,532
3,011
2,489
3,153
3,978
4,534
5,746
3,437
4,924
4,553
4,5534,9243,4375,7464,5343,9783,1532,4893,0112,5321,9092,4801,6011,3692,4447791,0191,1369817561,0802,637891,5081,5471,8711,2811,3901,3338658719857107731,69373001,25905881,5461,018
       Short-term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
181
0
192
198
203
208
213
194
213
232
252
258
263
269
275
560
572
584
284
211
21128458457256027526926325825223221319421320820319819201810000000000000000000000
       Accounts payable 
256
716
197
0
583
0
384
1,391
402
212
467
227
134
541
641
158
426
251
244
49
2,490
142
99
288
282
299
87
1,640
274
323
1,946
100
422
608
531
635
1,140
1,528
2,619
815
1,351
903
9031,3518152,6191,5281,1406355316084221001,9463232741,64087299282288991422,490492442514261586415411342274672124021,39138405830197716256
       Other Current Liabilities 
762
830
391
0
676
0
347
302
371
498
518
644
731
792
749
1,123
1,445
1,155
1,264
34
147
453
475
77
662
522
489
596
882
1,084
1,585
1,577
1,858
2,145
1,695
2,249
2,563
2,446
2,555
2,038
3,289
3,439
3,4393,2892,0382,5552,4462,5632,2491,6952,1451,8581,5771,5851,08488259648952266277475453147341,2641,1551,4451,12374979273164451849837130234706760391830762
   > Long-term Liabilities 
0
0
0
0
0
0
0
13
13
22
19
25
27
28
30
35
35
0
6
0
0
0
327
0
213
161
108
54
0
760
698
635
559
491
422
354
284
211
137
62
38
41
413862137211284354422491559635698760054108161213032700060353530282725192213130000000
       Long term Debt Total 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
467
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000000000004670000000000000000000000
       Other Liabilities 
0
0
0
0
0
0
0
14
13
22
20
25
26
29
30
16
14
7
2
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000000000000027141630292625202213140000000
> Total Stockholder Equity
587
22,481
24,231
0
18,314
0
19,866
19,020
14,067
15,053
13,358
18,346
16,526
14,731
12,429
10,130
13,769
20,308
19,801
557
16,570
287
15,223
0
10,238
7,736
14,625
10,930
20,010
15,475
10,836
7,520
2,882
14,613
8,994
4,713
202
22,308
15,470
11,500
47,248
64,180
64,18047,24811,50015,47022,3082024,7138,99414,6132,8827,52010,83615,47520,01010,93014,6257,73610,238015,22328716,57055719,80120,30813,76910,13012,42914,73116,52618,34613,35815,05314,06719,02019,866018,314024,23122,481587
   Retained Earnings -195,318-190,259-184,920-180,641-173,843-167,889-163,228-158,831-153,420-148,327-143,260-139,985-135,164-130,119-126,116-122,207-119,340-116,636-113,829-101,806-145,420-98,928-141,258-96,587-99,061-107,864-110,586-110,223-108,760-104,316-101,892-95,857-98,917-98,104-95,816-89,5290-82,6760-82,901-101,4850
   Accumulated Other Comprehensive Income 
0
1,919
1,141
0
1,563
0
1,898
1,772
1,915
1,364
1,079
1,204
1,286
1,429
1,299
1,325
1,096
0
806
0
582
0
319
0
-1,953
-1,775
-1,567
-1,591
-1,455
-1,216
-1,273
-1,506
-1,245
-738
-898
-853
-830
-780
-952
-835
-892
-993
-993-892-835-952-780-830-853-898-738-1,245-1,506-1,273-1,216-1,455-1,591-1,567-1,775-1,95303190582080601,0961,3251,2991,4291,2861,2041,0791,3641,9151,7721,89801,56301,1411,9190
   Capital Surplus 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
128,826
0
138,395
138,632
0
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000000138,632138,3950128,826000000000000000000000000
   Treasury Stock000000000000000000000000000000000000000000



5.3. Balance Sheets

Currency in USD. All numbers in thousands.




5.4. Cash Flows

Currency in USD. All numbers in thousands.




5.5. Income Statements

Currency in USD. All numbers in thousands.